Aptuit has relocated its recently acquired subsidiary, Kuecept, to its Oxford UK site, and has added further formulation and safety assessment capacity to meet sustained customer demand for investigational new drug (IND) de-risking and enabling packages. Kuecept, now part of the Aptuit group, provides phase appropriate pre-formulation testing, preclinical dose-vehicle screening, and formulation development. Kuecept has expertise in respiratory, parenteral, and oral formulation development. It also offers formulation rescue consultancy supporting companies moving active pharmaceutical ingredients (APIs) through IND/clinical trial agreement-enabling safety assessment.

Source: Aptuit